Pfizer-BioNTech vaccine sharply reduces symptomatic Covid-19 in the real world, Israeli researchers say

Pfizer-BioNTechs

Covid-19 vaccine



Pfizer-BioNTech vaccine sharply reduces symptomatic Covid-19 in the real world, Israeli researchers say

Pfizer-BioNTech vaccine sharply reduces symptomatic Covid-19 in the real world, Israeli researchers say

appears to reduce symptomatic coronavirus infections by more than 90% in the real world, Israeli researchers said Sunday.

The findings, while preliminary, suggest that the vaccine remains remarkably effective in a mass vaccination campaign outside the carefully controlled conditions of a clinical trial.

The Clalit Research Institute, part of a large Israeli health system, analyzed data on 1.2 million people, about half of whom had received the Pfizer-BioNTech vaccine. Researchers compared patients who received the vaccine with similar individuals who hadnt.



Pfizer-BioNTech vaccine sharply reduces symptomatic Covid-19 in the real world, Israeli researchers say

Pfizer-BioNTech vaccine sharply reduces symptomatic Covid-19 in the real world, Israeli researchers say

The rate of symptomatic Covid-19 meaning people who were infected with the coronavirus and felt sick decreased by 94% among people who received two doses of the vaccine, according to a press release from Clalit. The rate of serious illness decreased by 92%.

Full details of the study werent immediately available, and the research hasnt yet been peer-reviewed. Still, the findings are consistent with data from Pfizers own vaccine trial which found that the vaccine conferred 95% protection against symptomatic Covid-19.

The affirmation is really important, says CNN Medical Analyst Dr. Leana Wen, an emergency physician and visiting professor at George Washington University Milken Institute School of Public Health.



Pfizer-BioNTech vaccine sharply reduces symptomatic Covid-19 in the real world, Israeli researchers say

Pfizer-BioNTech vaccine sharply reduces symptomatic Covid-19 in the real world, Israeli researchers say

You want to make sure that the study results that we initially were seeing in tens of thousands of people is reflected when, when the population is in the millions.

In the Pfizer trial, researchers randomly assigned patients to receive

best font for title